Table 1.
Baseline and disease characteristics by dose group
| Q3W dosing | Q1W dosing | All patients (N = 39) |
||||||
|---|---|---|---|---|---|---|---|---|
| 0.3 mg/kg (n = 3) |
0.6 mg/kg (n = 3) |
1.2 mg/kg (n = 3) |
1.8 mg/kg (n = 7) |
2.4 mg/kg (n = 17) |
0.8 mg/kg (n = 3) |
1.1 mg/kg (n = 3) |
||
| Age (yr), median (range) |
62 (52−73) | 66 (51−71) | 58 (56−62) | 65 (51−73) | 63 (48−75) | 69 (42−80) | 63 (59−78) | 63 (42−80) |
| Sex, male | 1 (33%) | 2 (67%) | 3 (100%) | 4 (57%) | 9 (53%) | 1 (33%) | 1 (33%) | 21 (54%) |
| ECOG performance status, median (range) |
1 (1−1) | 1 (1−1) | 1 (0−1) | 1 (0−2) | 1 (0−2) | 1 (0−1) | 1 (0−1) | 1 (0−2) |
| Duration of malignancy (months), median (range) |
91 (46−101) | 88 (47−116) | 93 (48−100) | 79 (11−106) | 92 (8−141) | 54 (37−125) | 26 (21−171) | 88 (8−171) |
| Prior cancer treatment, Systemic therapy, median (range) |
||||||||
| Systemic therapy | 8 (7−9) | 6 (5−6) | 9 (5−10) | 4 (2−10) | 5 (2−13) | 7 (3−8) | 4 (3−7) | 6 (2−13) |
ECOG Eastern Cooperative Oncology Group